Anti il6 neutralizing antibodies

Manufactured by R&D Systems

Anti-IL6 neutralizing antibodies are laboratory reagents used for research purposes. They are designed to bind and neutralize the interleukin-6 (IL-6) cytokine, which plays a role in immune response and inflammation. These antibodies can be used in various in vitro and in vivo experimental models to study the function and signaling of IL-6.

Automatically generated - may contain errors

Lab products found in correlation

Close spelling variants of this product

Anti-mouse TNFα- and IL6-neutralizing antibodies Neutralizing antibodies

3 protocols using anti il6 neutralizing antibodies

Curcumin Cytotoxicity in IL-6-Induced Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

ChaGo-K-1 and COLO-205 cells were incubated with recombinant IL-6 (at 50 ng/ml; R&D Systems) for 6 h and subsequently incubated with curcumin (40 μM) for 24 h. Viability was assessed by MTT.
hCG tumor-conditioned medium (obtained upon incubation of ChaGo-K-1 and COLO-205 with hCG for 24 h) was incubated with peripheral blood adherent cells (PBACs; obtained upon plastic adherence of human PBMCs) for 24 h. Levels of IL-6 and TNF-α in PBAC supernatants were determined by ELISA (eBiosciences). The ability of such PBAC supernatants to mediate resistance to curcumin (at 40 μM) in naïve ChaGo-K-1 and COLO-205 cells was assessed by MTT; the contribution of elicited IL-6 to these effects was assessed using anti-IL6 neutralizing antibodies (500 ng/ml; R&D Systems).

Sahoo S., Singh P., Kalha B., Singh O, & Pal R. (2015). Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets. BMC Cancer, 15, 931.

+ Open protocol

+ Expand

Modulating BMP and IL-6 Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were treated with 1 or 3 μg/ml anti-BMP4, anti-BMP6, anti-BMP7, or anti-IL6 neutralizing antibodies (R&D Systems). 3 μg/ml Isotope matched anti-IgG was used as a control (R&D Systems). Human recombinant BMP6 (R&D systems), BMP4 and BMP7 (GIBCO) were used at 50 – 200 ng/ml for 24 hrs. Cells were treated with human recombinant IL6 (Peprotech) for 24 hours.

Tesfay L., Clausen K.A., Kim J.W., Hegde P., Wang X., Miller L.D., Deng Z., Blanchette N., Arvedson T., Miranti C.K., Babitt J.L., Lin H.Y., Peehl D.M., Torti F.M, & Torti S.V. (2015). Hepcidin regulation in prostate and its disruption in prostate cancer. Cancer research, 75(11), 2254-2263.

+ Open protocol

+ Expand

Coculture of CRC Cells and Stromal Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

CRC cells were cocultured with MSC, or normal skin fibroblasts as controls, at different ratios, for 5 days in tumor cell medium. In specific experiments, recombinant TGF-β (100 ng/mL, R&D Systems) or IL-6 (10 ng/mL, R&D Systems), the TGF-β inhibitors latency-associated peptide (LAP) (10 µg/mL, R&D Systems) or SB431542 (10 µg/mL, Sigma) or anti-IL-6 neutralizing antibodies (10 µg/mL, R&D Systems) were added to cultures as indicated. The lack of effect by the TGF-β inhibitors on basal E-cadherin expression was verified in preliminary experiments (data not shown). In experiments aimed at evaluating the role of cell-to-cell contact, MSC and tumor cells were plated in the upper and lower chambers, respectively, of transwell plates (0.4 µm pore size, Corning, Lowell, MA). Alternatively, tumor cells were cultured in the presence of MSC-conditioned medium harvested every 48 hr. Monocultures of MSC or tumor cells were used as controls. At the end of culture periods, supernatants were collected and cells were harvested and used for subsequent analyses.

Mele V., Muraro M.G., Calabrese D., Pfaff D., Amatruda N., Amicarella F., Kvinlaug B., Bocelli-Tyndall C., Martin I., Resink T.J., Heberer M., Oertli D., Terracciano L., Spagnoli G.C, & Iezzi G. (2014). Mesenchymal stromal cells induce epithelial-to-mesenchymal transition in human colorectal cancer cells through the expression of surface-bound TGF-β. International Journal of Cancer. Journal International du Cancer, 134(11), 2583-2594.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!